Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 09:01 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP)...
September 27, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at the LD Micro Main Event XVI

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD...
September 26, 2023 08:00 ET | Source: Indaptus Therapeutics

Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A...
September 19, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to...
September 06, 2023 08:05 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the...
August 14, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and...
August 10, 2023 08:45 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the next cohort of patients NEW YORK, Aug. 10,...
August 07, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...
June 15, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...
May 31, 2023 08:30 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...